Treatment Decision-Making and ALPHA3 Trial Implications

Dr. Melody describes her approach to discordant results (negative PET-CT, positive ctDNA), emphasizing closer monitoring rather than immediate treatment changes. She increases surveillance frequency, ensures in-person physical examinations, trends laboratory values including lactate dehydrogenase and complete blood counts, and performs additional imaging when PET scans show equivocal findings like Deauville 3 with likely reactive lymph nodes. This approach aims to capture earlier relapse while minimizing harm through judicious additional testing.

Recent data suggests patients with higher inflammatory markers (ferritin, C-reactive protein, lactate dehydrogenase) at CAR-T cell therapy experience worse outcomes, supporting earlier relapse detection for improved cellular immunotherapy results. However, she emphasizes not sending patients immediately for biopsy or proceeding directly to next-line therapy based solely on single ctDNA results.

Dr. Roschewski acknowledges that while physicians claim blood tests won't change management, Dr. Melody described approximately 4 different management approaches based on test results. These nuanced changes prove difficult to capture in clinical trials but reflect real-world practice evolution. He draws parallels to PET scan adoption, where initial uncertainty about interpretation led to refined criteria development from binary positive/negative assessments to nuanced Deauville scoring systems.

Both physicians would order ctDNA as adjuncts to PET scans for most patients except baseline low-risk cases, where low relapse probability makes false-positives more likely than helpful results. Neither would routinely recommend CAR-T therapy based solely on molecular-only disease, though exceptional circumstances (tremendously high-risk, young patients with full risk understanding) might justify consideration, similar to historical consolidative autologous transplant approaches.

The ALPHA3 trial represents a critical randomized phase 2 study investigating ctDNA-guided treatment using allogeneic CAR-T cells. The control arm receives standard imaging-based follow-up, while the intervention arm uses ctDNA results for treatment decisions in patients with negative PET scans or partial responses. This "domino trial" could validate strategies for improving cure rates versus waiting for radiographic disease, though not all detectable ctDNA patients will relapse (15-30% across studies). Success depends on manageable toxicity profiles and demonstration of survival benefits justifying treatment of some patients who might never progress.